Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.76 |
| ▸ | HTR6 | P50406 | 3/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | GLA | P06280 | 1/20 | 0.48 |
| ▸ | CASP1 | P29466 | 1/20 | 0.48 |
| ▸ | CASP7 | P55210 | 1/20 | 0.48 |
| ▸ | SCARB1 | Q8WTV0 | 1/20 | 0.45 |
| ▸ | PTGDR2 | Q9Y5Y4 | 4/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | KRAS | P01116 | 2/20 | 0.42 |
| ▸ | RORC | P51449 | 2/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10152135 | 0.82 | HSD17B10 (0.71) | HSD17B10HTR6KDM4EKMT2AMEN1 | |
| SCHEMBL13677415 | 0.81 | HSD17B10 (0.70) | HSD17B10KDM4EKMT2AMEN1GLA | |
| SCHEMBL28795369 | 0.81 | KDM4E (0.49) | HSD17B10KDM4EKMT2AMEN1LMNA | |
| SCHEMBL15899412 | 0.79 | HTR6 (0.57) | HSD17B10HTR6KDM4EKMT2AMEN1 | |
| SCHEMBL15899530 | 0.77 | HTR6 (0.55) | HSD17B10HTR6KDM4EKMT2AMEN1 | |
| SCHEMBL15899271 | 0.76 | HTR6 (0.54) | HSD17B10HTR6KDM4EKMT2AMEN1 | |
| SCHEMBL13677430 | 0.76 | HTR6 (0.51) | HSD17B10HTR6KDM4EKMT2AMEN1 | |
| SCHEMBL10152245 | 0.76 | KDM4E (0.60) | HSD17B10KDM4EKMT2AMEN1PTGDR2 | |
| SCHEMBL13677414 | 0.75 | PTGDR2 (0.81) | HSD17B10PTGDR2 | |
| SCHEMBL6482125 | 0.72 | HTR6 (0.56) | HSD17B10HTR6KDM4EKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2423190-A1 | Compounds Exhibiting PGD 2 Receptor Antagonism | Shionogi&Co., Ltd. (JP) | 2012-02-29 | — | — | EP | disclosed |
| US-20090258922-A1 | COMPOUND EXHIBITING PGD2 RECEPTOR ANTAGONIST | SHIONOGI & CO., LTD. | 2009-10-15 | — | — | US | disclosed |
| US-7534897-B2 | Indole arylsulfonaimide compounds exhibiting PGD 2 receptor antagonism | SHIONOGI & CO., LTD. (JP) | 2009-05-19 | — | — | US | disclosed |
| US-7534897-B2 | Indole arylsulfonaimide compounds exhibiting PGD 2 receptor antagonism | SHIONOGI & CO., LTD. (JP) | 2009-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090258922-A1 | COMPOUND EXHIBITING PGD2 RECEPTOR ANTAGONIST | CYSLTR2, CYSLTR1, HRH2 | HSD17B10 2363/4885HTR6 409/4885KDM4E 2938/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.